Company / R&D per Share
Vaxcyte, Inc. R&D per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$5.84
FY2025
5-year range
$1.51 / $5.84
FY2021-FY2025
Trend
+49.4%
vs FY2024
Sector context
#27 of 208
Health Care
What the data says
Vaxcyte, Inc.'s r&d per share of $5.84 is higher than 87% of companies in the Health Care sector (FY2025). R&D per Share has increased for 4 consecutive years, from $1.51 in FY2021 to $5.84 in FY2025.
Based on SEC 10-K filings.
5.84 in FY2025 with a 5-year CAGR of +18.6%. Top quartile in the Health Care sector.
Improved from $3.42 to $5.84 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +30.7%
- 5-Year CAGR
- +18.6%
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 208This company $5.84 Sector average $28.82
▼
-79.7% below sector average
Key checks
Key Insights
- Vaxcyte, Inc.'s r&d per share has grown for 4 consecutive years.
- In FY2025, r&d per share increased 49.4% year-over-year.
- Ranks #27 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.94 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.84 | +49.4% |
| FY2024 | $3.91 | +14.2% |
| FY2023 | $3.42 | +31.0% |
| FY2022 | $2.61 | +73.0% |
| FY2021 | $1.51 | -39.3% |
| FY2020 | $2.49 | -79.3% |
| FY2019 | $12.02 | +44.7% |
| FY2018 | $8.30 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026